Skip to main content

Table 2 Wald tests for models with GBM classification and study origin, and interaction

From: DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients

Characteristic MES RTK I RTK II GBM classification Study GBM Class x Study
Mean (sd) Mean (sd) Mean (sd) *F-value Pr(> F) *F-value Pr(> F) *F-value Pr(> F)
Patient age [yrs] 60.175 (10.853) 61.075 (11.927) 60.834 (10.83) 0.216 0.806 52.158  < 0.001 0.747 0.612
DNAm age [yrs] 89.246 (21.746) 94.538 (24.999) 104.106 (26.163) 10.717  < 0.001 4.670 0.003 1.896 0.079
Age accel [yrs] 29.072 (19.566) 33.463 (21.956) 43.273 (25.652) 10.480  < 0.001 1.457 0.225 2.456 0.024
HM-purity 0.592 (0.104) 0.817 (0.105) 0.802 (0.099) 68.162  < 0.001 2.288 0.078 1.086 0.369
Global HME 0.556 (0.029) 0.571 (0.027) 0.545 (0.029) 18.557  < 0.001 0.029 0.994 0.394 0.883
HME prom CpG 0.362 (0.032) 0.361 (0.03) 0.363 (0.029) 0.086 0.917 0.147 0.932 1.815 0.094
  1. *F-values are computed with covariance matrix, estimated by sandwich estimation (type HC3) to reduce the effect of the variance heterogeneity